Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Phase 2

Completed

Conditions: Hepatitis B Immunisation
Haemophilus Influenzae Type b Immunisation
Varicella Immunisation
Pertussis Immunisation
Polio Immunisation
Pneumococcal Immunisation
Diphtheria Immunisation
Mumps Immunisation
Tetanus Immunisation
Measles Immunisation

Interventions: Biological: Pneumococcal Conjugate Vaccine formulation 1
Biological: Pneumococcal Conjugate Vaccine formulation 2
Biological: Pneumococcal Conjugate Vaccine formulation 3
Biological: Measles, Mumps, and Rubella Virus Vaccine Live
Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
Biological: Varicella Virus Vaccine Live
Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
Biological: Hepatitis B Vaccine* [Recombinant] *as applicable

Registration Number: NCT04398706

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Brief Summary: Primary objectives:

* To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).

* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)

* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in infants (Groups 5-8)

* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in infants (Groups 5-8)

Secondary objectives:

* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)

* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in a subset of infants (Groups 5-8)

* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in a subset of infants (Groups 5-8)

* In toddlers: to describe the Ab responses against Pentacel antigens before and 1 month following injection of Pentacel

* In infants: to describe the Ab responses against antigens of the routine pediatric vaccines (Pentacel, RotaTeq, ENGERIX-B, M-M-RII, and VARIVAX) when administered concomitantly with either SP0202 or Prevnar 13 (at pre-Dose 1 (as applicable) for RotaTeq, Diphteria, Tetanus and Pertussis antigens; at PD3 for ENGERIX-B, RotaTeq, and Pentacel; at PD4 for M-M-RII and VARIVAX\])

Detailed Description: For toddlers, the duration of each participant's participation in the study will be approximately 6 months for subjects enrolled in Groups 1, 2, 3, and 4.

For infants, the duration of each participant's participation in the study will be approximately 16 to 19 months for subjects enrolled in Groups 5, 6, 7, and 8.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 852

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 8	Measles, Mumps, and Rubella Virus Vaccine Live	Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 1	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 4	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 5	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 5	Pneumococcal Conjugate Vaccine formulation 1	Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 5	Varicella Virus Vaccine Live	Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 5	Rotavirus Vaccine, Live, Oral, Pentavalent	Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 6	Measles, Mumps, and Rubella Virus Vaccine Live	Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 6	Rotavirus Vaccine, Live, Oral, Pentavalent	Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 5	Measles, Mumps, and Rubella Virus Vaccine Live	Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 6	Pneumococcal Conjugate Vaccine formulation 2	Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 7	Hepatitis B Vaccine* [Recombinant] *as applicable	Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 8	Varicella Virus Vaccine Live	Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 8	Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]	Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 8	Hepatitis B Vaccine* [Recombinant] *as applicable	Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 7	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 8	Rotavirus Vaccine, Live, Oral, Pentavalent	Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 1	Pneumococcal Conjugate Vaccine formulation 1	One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 2	Pneumococcal Conjugate Vaccine formulation 2	One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 2	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 3	Pneumococcal Conjugate Vaccine formulation 3	One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 3	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 4	Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]	One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Group 5	Hepatitis B Vaccine* [Recombinant] *as applicable	Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 6	Varicella Virus Vaccine Live	Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 6	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 6	Hepatitis B Vaccine* [Recombinant] *as applicable	Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 7	Pneumococcal Conjugate Vaccine formulation 3	Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 7	Varicella Virus Vaccine Live	Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 7	Measles, Mumps, and Rubella Virus Vaccine Live	Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 7	Rotavirus Vaccine, Live, Oral, Pentavalent	Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Group 8	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)	Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable

Primary Outcome Measures

Name	Time	Method
Number of Participants With Immediate Adverse Events (AEs)	Up to 30 minutes after each vaccination	An AE was any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. Immediate events were recorded to capture medically relevant unsolicited systemic AEs (including those related to the product administered) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination and included both serious adverse events (SAEs) and non-serious unsolicited AEs.
Number of Participants With Solicited Injection Site Reactions	Up to 7 days after each vaccination	A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted in the protocol and CRB and were considered to be related to the product administered. An injection site reaction was an adverse reaction at and around the injection site which were commonly inflammatory reactions. Solicited injection site reactions included tenderness, erythema and swelling around the injection site and were planned to be collected and reported for SP0202/Prevnar 13 for both toddlers and infants.
Number of Participants With Solicited Systemic Reactions	Up to 7 days after each vaccination	A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, abnormal crying, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.
Number of Participants With Unsolicited AEs	Up to 30 days after each vaccination	An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which did not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both SAEs and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.
Number of Participants With SAEs and Adverse Event of Special Interest (AESIs)	From first dose vaccine administration (Day 1) until 6 months after the last dose administration, 490 days	An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. The following AE were captured as AESI throughout the study: Anaphylaxis defined as per the Brighton collaboration case definition, convulsions including febrile convulsions, hypotonic-hyporesponsive episode and apnea. Reported AEs for each arm were presented as pre-specified in protocol.
For Toddlers: Serotype Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each Pneumococcal Serotype at 30 Days Post-Dose	Day 30	The GMCs for serotype specific pneumococcal IgG antibodies were measured using pneumococcal capsular polysaccharide-electro-chemiluminescent assay (PnPS-ECL), a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
For Infants: Percentage of Participants With Serotype Specific IgG Concentration >=0.35 mcg/mL 30 Days Post-Dose 3	Day 150	Percentage of infants with serotype specific IgG concentration \>=0.35 mcg/mL for each pneumococcal serotype included in the SP0202 formulations were measured using ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 3	Day 150	The GMCs for serotype-specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 4	Day 330	The GMCs for serotype specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

Secondary Outcome Measures

Name	Time	Method
For Infants: Percentage of Participants With Antibody Responses to M-MRII and Varivax Antigens 30 Days Post-Dose 4	Day 330	Anti-measles antibodies were determined by bulk measles IgG enzyme immunoassay (EIA); anti-mumps antibodies by ELISA, anti-rubella antibodies by bulk rubella IgG EIA and anti-varicella antibodies were determined by glycoprotein ELISA to detect total IgG antibody to respective virus before and after vaccination with a virus-containing vaccine. Percentage of participants with anti-measles antibody concentrations \>=255 mIU/mL, anti-mumps antibody concentrations: \>=10 antibody units/mL, anti-rubella antibody concentrations \>=10 IU/mL and anti-varicella concentrations \>=5 units/mL is reported in this outcome measure.
For Toddlers: Serotype Specific OPA Geometric Mean Titers (GMTs) for Each Pneumococcal Serotype 30 Days Post-Dose	Day 30	The GMs for serotype specific OPA titers were measured using multiplex opsonophagocytic assay (MOPA) which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 3	Day 150	The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 4	Day 330	The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
For Infants: GMC of Anti-Rotavirus Serum Immunoglobulin A (IgA) Antibodies 30 Days Post-Dose 3	Day 150	Anti-rotavirus IgA antibodies in human serum were measured by enzyme linked immunosorbent assay (ELISA). A reference standard assayed on each plate was used to calculate the amount of specific anti-rotavirus IgA antibody in the units assigned by the reference standard.
For Infants: Percentage of Participants With Antibody Responses to Diphtheria, Tetanus and Polyribosylribitol Phosphate Antigens 30 Days Post-Dose 3	Day 150	Percentage of participants with toxoid concentration \>=0.10 mcg/mL for diphtheria and tetanus and \>=0.15 mcg/mL for PRP are presented. Anti-diphtheria and anti-tetanus concentrations were measured using electro-chemiluminescence assay (ECL) and anti-PRP concentrations were measured using a Farr-type radioimmunoassay.
For Infants: Percentage of Participants With Antibody Responses to Poliovirus 1, 2 and 3 30 Days Post-Dose 3	Day 150	Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. Response was defined as a titer \>=8.
For Infants: GMCs of Antibodies to Pertussis Antigens 30 Days Post-Dose 3	Day 150	Serum samples were collected for analysis by ECL to determine the GMC of antibodies to the following Pertussis antigens: Pertussis toxoid/toxin, Filamentous hemagglutinin, Pertactin and Fimbriae types 2 and 3.
For Infants: Percentage of Participants With Antibody Responses to Hepatitis-B Antigens 30 Days Post-Dose 3	Day 150	Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The VITROS ECi immunodiagnostic system uses an antibody mediated antigen sandwich formation to detect the presence of anti-hepatitis B surface antigen total immunoglobulin in human serum. The threshold presented is \>=10 milli international units (mIU).

Trial Locations

Locations (57): Pediatric Associates of Mt. Carmel Site Number : 8400005
🇺🇸
Cincinnati, Ohio, United States
Lincoln Pediatric Group Site Number : 8400125
🇺🇸
Lincoln, Nebraska, United States
Tribe Clinical Research Site Number : 8400025
🇺🇸
Greenville, South Carolina, United States
Dade Research Center Site Number : 8400122
🇺🇸
Miami, Florida, United States
Joint Clinical Trials Huntington Park Site Number : 8400030
🇺🇸
Huntington Park, California, United States
The Children's Clinic Of Jonesboro PA Site Number : 8400143
🇺🇸
Jonesboro, Arkansas, United States
Matrix Clinical Research Site Number : 8400059
🇺🇸
Los Angeles, California, United States
Orange County Research Institute Site Number : 8400060
🇺🇸
Ontario, California, United States
Homestead Medical Clinic, P.A. Site Number : 8400032
🇺🇸
Homestead, Florida, United States
International Research Partners, LLC Site Number : 8400077
🇺🇸
Doral, Florida, United States
Miami Clinical Research Site Number : 8400020
🇺🇸
Miami, Florida, United States
California Research Foundation Site Number : 8400052
🇺🇸
San Diego, California, United States
Southland Clinical Research Center Site Number : 8400040
🇺🇸
Bellflower, California, United States
Meridian Clinical Research, LLC Site Number : 8400112
🇺🇸
Baton Rouge, Louisiana, United States
Hutchinson Clinic Site Number : 8400074
🇺🇸
Hutchinson, Kansas, United States
Michael W. Simon, MD, PSC Site Number : 8400002
🇺🇸
Lexington, Kentucky, United States
Atrium Health Site Number : 8400124
🇺🇸
Charlotte, North Carolina, United States
Benchmark Research Site Number : 8400012
🇺🇸
Covington, Louisiana, United States
Ardmore Medical Research Site Number : 8400043
🇺🇸
Winston-Salem, North Carolina, United States
Sun Research Institute Site Number : 8400011
🇺🇸
San Antonio, Texas, United States
Javara Dallas Site Number : 8400135
🇺🇸
Dallas, Texas, United States
North Texas Clinical Trials Site Number : 8400015
🇺🇸
Fort Worth, Texas, United States
Investigational Site Number : 3400001
🇭🇳
San Pedro Sula, Honduras
Investigational Site Number : 1240006
🇨🇦
Hamilton, Ontario, Canada
Amber Clinical Research, LLC Site Number : 8400019
🇺🇸
Miami, Florida, United States
Javara Fayetteville Site Number : 8400139
🇺🇸
Fayetteville, Georgia, United States
DCOL Center for Clinical Research Site Number : 8400107
🇺🇸
Longview, Texas, United States
Meridian Clinical Research Washington DC Site Number : 8400119
🇺🇸
Washington, District of Columbia, United States
Javara Albany Site Number : 8400140
🇺🇸
Albany, Georgia, United States
Matrix Clinical Research Huntington Park Site Number : 8400058
🇺🇸
Huntington Park, California, United States
Centricity Research Talbotton - DBA IACT Health Research at Talbotton Site Number : 8400062
🇺🇸
Columbus, Georgia, United States
Children's Mercy Hospital Site Number : 8400008
🇺🇸
Kansas City, Missouri, United States
Dumog Research Site Number : 8400134
🇺🇸
Smyrna, Georgia, United States
Bingham Memorial Hospital Site Number : 8400067
🇺🇸
Blackfoot, Idaho, United States
Leavitt Clinical Research Site Number : 8400127
🇺🇸
Idaho Falls, Idaho, United States
Cheraw Pediatrics Site Number : 8400017
🇺🇸
Cheraw, South Carolina, United States
Pininos Pediatric Services Site Number : 8400121
🇺🇸
El Paso, Texas, United States
Houston Clinical Research Associates Site Number : 8400023
🇺🇸
Houston, Texas, United States
Tekton Research Site Number : 8400076
🇺🇸
San Antonio, Texas, United States
Investigational Site Number : 3400002
🇭🇳
Municipio Del Distrito Central, Honduras
FMC Science, LLC Site Number : 8400086
🇺🇸
Lampasas, Texas, United States
Biopharma Informatic Site Number : 8400066
🇺🇸
McAllen, Texas, United States
MultiCare Institute for Research & Innovation Site Number : 8400024
🇺🇸
Spokane, Washington, United States
Benchmark Research San Antonio Site Number : 8400129
🇺🇸
San Antonio, Texas, United States
Investigational Site Number : 1240001
🇨🇦
Halifax, Nova Scotia, Canada
Investigational Site Number : 6300002
🇵🇷
Bayamón, Puerto Rico
Investigational Site Number : 6300001
🇵🇷
San Juan, Puerto Rico
Investigational Site Number : 6300004
🇵🇷
Guayama, Puerto Rico
Investigational Site Number : 1240002
🇨🇦
Vancouver, British Columbia, Canada
Javara Annapolis Site Number : 8400137
🇺🇸
Annapolis, Maryland, United States
Boeson Research Site Number : 8400004
🇺🇸
Missoula, Montana, United States
Velocity Clinical Research Lafayette Site Number : 8400132
🇺🇸
Lafayette, Louisiana, United States
Meridian Clinical Research Site Number : 8400102
🇺🇸
Grand Island, Nebraska, United States
Jedidiah Clinical Research Site Number : 8400049
🇺🇸
Tampa, Florida, United States
Pediatric Infectious Diseases Research Site Number : 8400104
🇺🇸
Omaha, Nebraska, United States
Qualmedica Research, LLC Site Number : 8400084
🇺🇸
Bowling Green, Kentucky, United States
Javara Chevy Chase Site Number : 8400138
🇺🇸
Chevy Chase, Maryland, United States